About | Free Trial

Last Update

2016-07-28T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Nicholas Cosford?

Dr. Nicholas Cosford Dp

Professor

Sanford-Burnham Medical Research Institute

Direct Phone: (858) ***-****       

Email: n***@***.org

Sanford-Burnham Medical Research Institute

10901 North Torrey Pines Road

La Jolla, California 92037

United States

Company Description

Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in... more

Find other employees at this company (971)

Background Information

Employment History

Associate Professor

Burnham Institute

Senior Investigator

Merck & Co. , Inc.

Affiliations

Scientific Advisory Board Member
Plex Pharmaceuticals Inc

Scientific Advisory Board Member
CalAsia Pharmaceuticals Inc

Education

Ph.D.

Burnham Institute for Medical Research

Web References (68 Total References)


Nicholas DP Cosford, ...

www.plexpharma.com [cached]

Nicholas DP Cosford, PhD

Dr. Cosford is Professor at Sanford Burnham Medical Research Institute, La Jolla, California. His research is involved in investigating the interactions of small molecule compounds with therapeutically important proteins and cellular signaling pathways. One aspect of his research emphasizes the use of medicinal chemistry and chemical biology approaches to probe intracellular pathways that regulate cell survival and cell growth. Another area of active research is the development of synthetic chemistry methodology using microfluidic technology for the rapid synthesis of biologically active small molecules. Therapeutically, his group is primarily focused on the discovery and optimization of compounds that have the potential to treat cancer, CNS diseases and infectious diseases. He has more than 20 years of experience leading small-molecule drug discovery projects in the pharmaceutical industry. At Sibia Neurosciences and at Merck Research Laboratories he directed multidisciplinary research teams focused on small- molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase. Examples include taking a nicotinic receptor agonist (Altinicline, SIB-1508Y) from initiation of research through to Phase II clinical for PD; taking mGluR5 negative allosteric modulators from HTS hits through in vivo proof-of-concept to Phase I clinical (ongoing); and design, synthesis and optimization of an mGluR5 PET tracer clinical candidate; design, synthesis and optimization of an Akt allosteric inhibitor preclinical candidate. To date, he has published more than 55 peer reviewed scientific publications, has more than 30 issued patents, and more than 30 additional patent applications pending. In 2006 he received the FRAXA Research Foundation Award for Outstanding Contributions to Fragile X Research.


Faculty Mentor: Nicholas ...

sbpdiscovery.org [cached]

Faculty Mentor: Nicholas Cosford

...
SBPdiscovery.org > Talent > Nicholas Cosford
Nicholas Cosford
Nicholas Cosford, Ph.D. [La Jolla]
...
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches.
...
Dr. Cosford joined Sanford-Burnham faculty in January 2008.
...
About Nicholas Cosford
Experience
Dr. Cosford joined Sanford-Burnham faculty in January 2008. Prior to that he was Project Manager for the Conrad Prebys Center for Chemical Genomics from 2005 to 2008 and has been Director of Medicinal Chemistry at Sanford-Burnham La Jolla site since 2006. Dr. Cosford has over 15 years experience leading small-molecule drug discovery projects in the pharmaceutical industry, and more recently at Sanford-Burnham. At Sibia Neurosciences and at Merck Research Laboratories he directed multidisciplinary research teams focused on small molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase. Examples include taking a nicotinic receptor agonist (Altinicline, SIB-1508Y) from initiation of research through to Phase II clinical; taking mGluR5 negative allosteric modulators from HTS hits through in vivo proof-of-concept to IND status; and design, synthesis and optimization of an mGluR5 PET tracer clinical candidate. Dr. Cosford's research in the areas of medicinal chemistry and small molecule synthesis has resulted in more than 50 peer reviewed scientific publications, 21 issued patents, and more than 25 additional patent applications pending. In 2006 Dr. Cosford received the FRAXA Research Foundation Award for Outstanding Contributions to Fragile X Research.


Graduate School Faculty

www.sbpdiscovery.org [cached]

Nicholas Cosford, Ph.D.

Associate Director of Translational Research, NCI-Designated Cancer Center Professor, NCI-Designated Cancer Center
...
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.


Prof. Nicholas Cosford, ...

www.calasiapharma.com [cached]

Prof. Nicholas Cosford, PhD

Dr. Cosford is Professor at Sanford Burnham Medical Research Institute, La Jolla, California. His research is involved in investigating the interactions of small molecule compounds with therapeutically important proteins and cellular signaling pathways. One aspect of his research emphasizes the use of medicinal chemistry and chemical biology approaches to probe intracellular pathways that regulate cell survival and cell growth. Another area of active research is the development of synthetic chemistry methodology using microfluidic technology for the rapid synthesis of biologically active small molecules. Therapeutically, his group is primarily focused on the discovery and optimization of compounds that have the potential to treat cancer, CNS diseases and infectious diseases. He has more than 20 years of experience leading small-molecule drug discovery projects in the pharmaceutical industry. At Sibia Neurosciences and at Merck Research Laboratories he directed multidisciplinary research teams focused on small-molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase. Examples include taking a nicotinic receptor agonist (Altinicline, SIB-1508Y) from initiation of research through to Phase II clinical for PD; taking mGluR5 negative allosteric modulators from HTS hits through in vivo proof-of-concept to Phase I clinical (ongoing); and design, synthesis and optimization of an mGluR5 PET tracer clinical candidate; design, synthesis and optimization of an Akt allosteric inhibitor preclinical candidate. To date, he has published more than 55 peer reviewed scientific publications, has more than 30 issued patents, and more than 30 additional patent applications pending. In 2006 he received the FRAXA Research Foundation Award for Outstanding Contributions to Fragile X Research.


Graduate School Faculty

www.sanfordburnham.org [cached]

Nicholas Cosford, Ph.D.

Professor, NCI-Designated Cancer Center Cell Death and Survival Networks Program
Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.

Similar Profiles

Other People with this Name

Other people with the name Cosford

Kirsty Cosford
Lincoln House

Kathleen Cosford
Reho Travel Pty Ltd

Bob Cosford
Global Cutting Technologies Ltd

John Cosford
Wilko

Faye Cosford
Asthma UK

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory